A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Vitamin D

1979 • 3,814 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 • 828 citations

Proceedings of the American Association for Cancer Research.

2001 • 654 citations

1,25-DIHYDROXYVITAMIN D₃AND MALIGNANT MELANOMA: THE PRESENCE OF RECEPTORS AND INHIBITION OF CELL GROWTH IN CULTURE

1981 • 560 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 490 citations

Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.

1994 • 489 citations

Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.

1993 • 475 citations

Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

2002 • 318 citations

Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.

1987 • 312 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

2002 • 244 citations

The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.

1992 • 226 citations

Anti-tumor activity of calcitriol: pre-clinical and clinical studies

2004 • 190 citations

Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.

2001 • 185 citations

A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.

1999 • 181 citations

1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo.

1999 • 157 citations

Vitamin D3-induced Apoptosis of Murine Squamous Cell Carcinoma Cells

2001 • 141 citations

Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma

2005 • 133 citations

A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation.

2001 • 130 citations

Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel

2002 • 127 citations

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

2003 • 126 citations

1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20)

1986 • 116 citations

Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines.

1993 • 111 citations

Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line.

1992 • 108 citations

A Phase I trial of pulse calcitriol in patients with refractory malignancies

2001 • 102 citations

BRIEF COMMUNICATION: Growth Control of Human Colon Cancer Cells by Vitamin D and Calcium In Vitro

1992 • 101 citations

A Vitamin D₃Analog Induces a G1-Phase Arrest in CaCo-2 Cells by Inhibiting Cdk2 and Cdk6: Roles of Cyclin E, p21^Waf1, and p27^Kip11

2000 • 92 citations

Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid.

1996 • 87 citations

Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression

1998 • 84 citations

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

2002 • 67 citations

Pharmacokinetics of 1α,25-Dihydroxyvitamin D<sub>3</sub> in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses

2004 • 65 citations

Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer

2005 • 53 citations

Vitamin D treatment in myelodysplastic syndromes

1998 • 45 citations

Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC)

2005 • 44 citations

Differentiating and antitumor activities of 1α,25‐dihydroxyvitamin D₃ in vitro and 1α‐hydroxyvitamin D₃ in vivo on human osteosarcoma

1993 • 28 citations

Vitamin D₃ analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells

1996 • 27 citations

Calcipotriol Inhibits Autocrine Phosphorylation of EGF Receptor in a Calcium-Dependent Manner, a Possible Mechanism for Its Inhibition of Cell Proliferation and Stimulation of Cell Differentiation

2001 • 27 citations

Vitamin D3 analogue (EB 1089) inhibitsin vitro cellular proliferation of human colon cancer cells

1996 • 14 citations